Clinical trials: Antitumor Drug
Non-Small Cell Lung Cancer
A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA)
The purpose of this Phase II, open-label, multicentre, single-arm study is to assess efficacy and safety of durvalumab (MEDI4736) in combination with oleclumab (MEDI9447) in participants with locally advanced (Stage III)…
- Trial name
- LADOGA (NCT06606847)
- Testing
- Oleclumab, Durvalumab
- Where
- 11 sites in Russia
- Volunteers
- 30 people
- Sponsor
- AstraZeneca
Neoplasms, Breast
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
This study is designed to provide continued access to lapatinib as monotherapy or as part of a combination regimen to cancer subjects who are currently participating in a phase I trial that has met its study objectives.
- Trial name
- NCT00790816
- Testing
- Lapatinib in combination with an anti-cancer agent, Lapatinib, Lapatinib in combination with an anti-cancer agent as specified by parent protocol
- Where
- 23 sites in United States, Canada and 3 more
- Volunteers
- 500 people
- Sponsor
- Novartis Pharmaceuticals
Cancer
Open Label Clinical Trial of Intravenous Crotoxin Part 3
The primary objective of the study is to assess whether human subjects can be made tolerant to intravenously administered Crotoxin and achieve higher and more therapeutically effective doses levels without the previously reported…
- Trial name
- NCT01481532
- Testing
- Crotoxin
- Where
- France
- Volunteers
- 24 people
- Sponsor
- Celtic Biotech Ltd
Gynecological Malignancies
9MW2821 Combined With Other Antitumor Drugs in Patients With Advanced Gynecological Tumors
To evaluate the safety, tolerability, and preliminary efficacy of 9MW2821 in combination with other anti-tumor agents in patients with advanced gynecological malignancies.
- Trial name
- NCT06926998
- Testing
- 9MW2821+other anticancer therapy
- Where
- China
- Volunteers
- 260 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Advanced Solid Tumor
A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors
QLC5508 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells.
- Trial name
- NCT07256782
- Testing
- QLC5508, QL1706, Cisplatin/ Carboplatin
- Where
- China
- Volunteers
- 444 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Brain and Central Nervous System Tumors
A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma
The primary objective of this study is to evaluate the safety, efficacy and clinical activity of Pamiparib in combination with radiation therapy (RT) and/or temozolomide (TMZ) in participants with newly diagnosed or…
- Trial name
- NCT03150862
- Testing
- Pamiparib, TMZ, Radiation
- Where
- 22 sites in United States, Australia and 3 more
- Volunteers
- 116 people
- Sponsor
- BeiGene USA, Inc.
Atherosclerosis, Vascular Disease
LEVANT I, The Lutonix Paclitaxel-Coated Balloon for the Prevention of Femoropopliteal Restenosis
The purpose of the study is to assess the safety and efficacy of the Lutonix Catheter for treatment of stenosis of the femoropopliteal arteries by direct comparison to standard balloon angioplasty.
- Conditions
- Atherosclerosis, Vascular Disease, Arteriosclerosis
- Trial name
- LEVANT I (NCT00930813)
- Testing
- Lutonix Catheter, Standard uncoated Balloon Angioplasty Catheter
- Where
- 10 sites in Belgium, Germany
- Volunteers
- 101 people
- Sponsor
- C. R. Bard
Locally Advanced Rectal Cancer, Electrochemotherapy
Endoscopic Assisted Electrochemotherapy in Addition to Neoadjuvant Treatment of Locally Advanced Rectal Cancer
The purpose of this study is to evaluate the efficacy and safety of neoadjuvant electrochemotherapy on locally advanced rectal cancer (UICC II-III) in an intended curative clinical setting, using an endoscopic electroporation…
- Conditions
- Locally Advanced Rectal Cancer, Electrochemotherapy, Neoadjuvant Therapy, Down Staging
- Trial name
- nECT (NCT03040180)
- Testing
- Electrochemotherapy with bleomycin, EndoVE
- Where
- 2 sites in Denmark
- Volunteers
- 40 people
- Sponsor
- Zealand University Hospital
Breast Cancer
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called ARV-471) when given together with other medicines for the potential treatment of advanced or metastatic breast cancer.
- Trial name
- NCT05548127
- Testing
- ARV-471, Abemaciclib
- Where
- 37 sites in United States, Canada and 2 more
- Volunteers
- 37 people
- Sponsor
- Pfizer
Breast Neoplasms
An Observational Study Of Indian Breast Cancer Patients Receiving Adjuvant Therapy With Aromasin
To generate the following data from patients with early breast cancer treated with Aromasin® in the adjuvant setting in India. Efficacy of the treatment with Aromasin® Safety of the treatment with Aromasin®
- Trial name
- NCT00776659
- Testing
- Aromasin
- Where
- 4 sites in India
- Volunteers
- 39 people
- Sponsor
- Pfizer
Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma, Advanced or Metastatic KRAS-mutant Tumor in Colorectal Cancer
Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
This is a study designed to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of WEF-001 as monotherapy in patients with Advanced KRAS-mutant solid tumours.
- Conditions
- Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma, Advanced or Metastatic KRAS-mutant Tumor in Colorectal Cancer, Advanced or Metastatic KRAS-mutant Tumor in Non Small Cell Lung Cancer, Advanced Solid Tumors
- Trial name
- NCT07148128
- Testing
- WEF-001
- Where
- 4 sites in United States, Canada and 1 more
- Volunteers
- 110 people
- Sponsor
- Auricula Biosciences Inc.
KRAS G12C Mutation, KRAS G12S Mutation
A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
The goal of this clinical trial is to learn if KQB365 works to treat advanced solid tumor cancer in adults. It will also learn about the safety of KQB365.
- Conditions
- KRAS G12C Mutation, KRAS G12S Mutation, Solid Tumor Malignancies, CRC (Colorectal Cancer)
- Trial name
- NCT06720987
- Testing
- KQB365, Cetuximab, KQB198
- Where
- 11 sites in United States
- Volunteers
- 140 people
- Sponsor
- Kumquat Biosciences Inc.
Chemotherapeutic Agent Toxicity, Colorectal Cancer
Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy
RATIONALE: Chemoprotective drugs, such as calcium gluconate and magnesium sulfate, may prevent neurotoxicity caused by oxaliplatin.
- Conditions
- Chemotherapeutic Agent Toxicity, Colorectal Cancer, Neuropathy, Neurotoxicity
- Trial name
- NCT01099449
- Testing
- calcium gluconate, magnesium sulfate, oxaliplatin
- Where
- 405 sites in United States, Puerto Rico
- Volunteers
- 362 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Pneumonia, Pneumocystis Carinii, HIV Infections
A Study of Trimetrexate in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS Not Previously Treated for PCP
To evaluate the safety and effectiveness of trimetrexate (TMTX) given at increasing doses along with the leucovorin calcium (LCV) for treating Pneumocystis carinii pneumonia (PCP) in AIDS patients TMTX is an experimental new drug…
- Trial name
- NCT00000998
- Testing
- Trimetrexate glucuronate, Leucovorin calcium
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Non Muscle Invasive Bladder Cancer
A Prospective Open Label Comparative Dose Ranging Study Evaluating the Effect of Pre-TURBT Intravesical Instillation of Mitomycin C (MMC) Mixed With TC-3 Gel in Patients With Non Muscle Invasive Bladder Cancer (NMIBC)
This study is a prospective randomized open labeled dose ranging comparative study. Twenty four (24) patients with NMIBC who meet the inclusion/exclusion criteria will be recruited for the study following the initial diagnostic…
- Trial name
- NMIBC TURBT HG (NCT01799499)
- Testing
- TC-3 hydrogel
- Where
- Israel
- Sponsor
- UroGen Pharma Ltd.
Phlebitis
Effects of Topical Sesame Oil in the Prevention of Peripheral Venous Catheter Phlebitis: Clinical Trial.
Cancer is a disease that, despite having a higher cure rate, is currently on the rise, with an increase in the number of diagnoses.
- Trial name
- NCT06375850
- Testing
- Sesame oil, Saline solution
- Where
- Spain
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Hospital Universitario Marqués de Valdecilla
Anemia, Neoplasms
Cost-effectiveness Study of Epoetin Alfa and Darbepoetin Alfa in Adult Patients With Cancer Who Have Anemia
The purpose of this study is to evaluate the cost-effectiveness of epoetin alfa compared with darbepoetin alfa in the treatment of anemia in adults receiving chemotherapy for cancer.
- Trial name
- NCT00264108
- Testing
- Darbepoetin alfa, Epoetin alfa
- Where
- 20 sites in Netherlands
- Volunteers
- 492 people
- Sponsor
- Janssen-Cilag B.V.
Metastatic Neuroendocrine Tumor
Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors
This phase II trial compares the effect of adding triapine to lutetium Lu 177 dotatate versus lutetium Lu 177 dotatate alone (standard therapy) in shrinking tumors or slowing tumor growth in patients with neuroendocrine tumors…
- Trial name
- NCT05724108
- Testing
- Biospecimen Collection, Computed Tomography, Lutetium Lu 177 Dotatate
- Where
- 25 sites in United States
- Volunteers
- 94 people
- Sponsor
- National Cancer Institute (NCI)
Extensive-Stage Small Cell Lung Cancer, Extrapulmonary Neuroendocrine Carcinoma
Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer
Background: Small-cell lung cancer (SCLC) is the most deadly form of lung cancer. It kills at least 250,000 worldwide each year.
- Conditions
- Extensive-Stage Small Cell Lung Cancer, Extrapulmonary Neuroendocrine Carcinoma, Small Cell Carcinoma
- Trial name
- NCT07328490
- Testing
- Tarlatamab, Sacituzumab Govitecan
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Acute Adult T-Cell Leukemia/Lymphoma, Adult T-Cell Leukemia/Lymphoma
Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)
This phase I trial studies the side effects and best dose of lenalidomide when given together with usual combination chemotherapy (etoposide, prednisone, vincristine sulfate [Oncovin], cyclophosphamide, and doxorubicin…
- Conditions
- Acute Adult T-Cell Leukemia/Lymphoma, Adult T-Cell Leukemia/Lymphoma, Chronic Adult T-Cell Leukemia/Lymphoma, HTLV-1 Infection
- Trial name
- NCT04301076
- Testing
- Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography
- Where
- 19 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)